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Abstract
Mitogen-activated protein kinase phosphatase 1 (MKP-1) represses MAPK-driven signalling and plays an important anti-
inflammatory role in asthma and airway remodelling. Although MKP-1 is corticosteroid-responsive and increased by cAMP-
mediated signalling, the upregulation of this critical anti-inflammatory protein by long-acting b2-agonists and clinically-used
corticosteroids has been incompletely examined to date. To address this, we investigated MKP-1 gene expression and
protein upregulation induced by two long-acting b2-agonists (salmeterol and formoterol), alone or in combination with the
corticosteroid fluticasone propionate (abbreviated as fluticasone) in primary human airway smooth muscle (ASM) cells
in vitro. b2-agonists increased MKP-1 protein in a rapid but transient manner, while fluticasone induced sustained
upregulation. Together, long-acting b2-agonists increased fluticasone-induced MKP-1 and modulated ASM synthetic
function (measured by interleukin 6 (IL-6) and interleukin 8 (IL-8) secretion). As IL-6 expression (like MKP-1) is cAMP/
adenylate cyclase-mediated, the long-acting b2-agonist formoterol increased IL-6 mRNA expression and secretion.
Nevertheless, when added in combination with fluticasone, b2-agonists significantly repressed IL-6 secretion induced by
tumour necrosis factor a (TNFa). Conversely, as IL-8 is not cAMP-responsive, b2-agonists significantly inhibited TNFa-induced
IL-8 in combination with fluticasone, where fluticasone alone was without repressive effect. In summary, long-acting b2-
agonists increase fluticasone-induced MKP-1 in ASM cells and repress synthetic function of this immunomodulatory airway
cell type.
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Introduction
Asthma is a chronic airway disease characterized by excessive
inflammation. Corticosteroids are widely-used to repress inflam-
mation in asthma and control of asthma symptoms can be
improved by combination therapy with long-acting b2-agonists
[1,2,3]. There are a number of mechanisms by which this
enhanced anti-inflammatory effect might be achieved at the
cellular level: these include control of histone acetylation,
increased function of glucocorticoid receptor (GR) or the b2-
adrenergic receptor, and upregulation of anti-inflammatory
proteins (reviewed in [4]). Mitogen-activated protein kinase
phosphatase 1 (MKP-1) is one such anti-inflammatory protein
whose upregulation is increasingly recognized as an important
molecular mechanism responsible for the improved anti-inflam-
matory action of corticosteroids and long-acting b2-agonists in
combination.
MKP-1 is an immediate-early gene [5] that is corticosteroid-
responsive [6] and contains a cAMP-responsive element (CRE) in
its 59-promoter [7,8]. We and others have demonstrated that the
upregulation of MKP-1 by corticosteroids is responsible, in part,
for their anti-inflammatory actions in clinically-relevant airway cell
types such as airway smooth muscle (ASM) and bronchial
epithelial cells [9,10,11,12,13,14]. Moreover, MKP-1 mRNA
expression and protein upregulation can be enhanced by long-
acting b2-agonists [12,15]. The increased expression of MKP-1
may explain the beneficial effects of b2-agonists/corticosteroid
combination therapies in the repression of inflammatory gene
expression in asthma [12,16]. However the upregulation of this
critical anti-inflammatory protein by long-acting b2-agonists and
clinically-used corticosteroids has been incompletely examined to
date.
To address this gap in knowledge, the aim of this study is to
examine MKP-1 mRNA expression and protein upregulation
induced by two long-acting b2-agonists (salmeterol and formo-
terol), alone or in combination with the corticosteroid fluticasone
propionate (abbreviated as fluticasone). We will assess the anti-
inflammatory function of MKP-1 induced by these combination
therapies on the synthetic function of primary human ASM cell
in vitro by measuring repression of interleukin 6 (IL-6) and
interleukin 8 (IL-8); two cytokines known to be upregulated in a
MAPK-mediated manner [10,17,18].
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Materials and Methods
Cell Culture
Human bronchi were obtained from patients undergoing
surgical resection for carcinoma or lung transplant donors in
accordance with procedures approved by the Sydney South West
Area Health Service and the Human Research Ethics Committee
of the University of Sydney. ASM cells were dissected, purified
and cultured as previously described by Johnson et al. [19]. A
minimum of three different ASM primary cell cultures established
from individual patients were used for each experiment.
Unless otherwise specified, all chemicals used in this study were
purchased from Sigma-Aldrich (St. Louis, MO).
Western Blotting
MKP-1 was quantified by Western blotting using a rabbit
polyclonal antibody against MKP-1 (C-19: Santa Cruz Biotech-
nology, Santa Cruz, CA), compared to a-tubulin used as the
loading control (mouse monoclonal IgG1, DM1A: Santa Cruz
Biotechnology, Santa Cruz, CA). Primary antibodies were
detected with goat anti-mouse or anti-rabbit HRP-conjugated
Figure 1. Salmeterol increases fluticasone-induced MKP-1 protein upregulation. (A) Growth-arrested ASM cells were treated with vehicle,
salmeterol (100 nM), fluticasone (1 nM), salmeterol (100 nM)+fluticasone (1 nM), for 0, 0.5, 1, 2, 4, 8, and 24 h. MKP-1 protein (molecular
weight:,39 kDa) was quantified by Western blotting, using a-tubulin as the loading control (molecular weight: 55,kDa), where (A) illustrates
representative Western blots and (B) demonstrates densitometric analysis where results are expressed as fold increase over 0 h (mean+SEM values
from n=6–8 primary ASM cell cultures). Statistical analysis was performed using two-way ANOVA then Bonferroni’s post-test (where * indicates a
significant effect of salmeterol or fluticasone on MKP-1 protein upregulation, compared to vehicle-treated cells, and 1 indicates a significant effect of
salmeterol on fluticasone-induced MKP-1 (P,0.05)).
doi:10.1371/journal.pone.0059635.g001
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secondary antibodies (Cell Signaling Technology) and visualized
by enhanced chemiluminescence (PerkinElmer, Wellesley, MA).
Real-time RT-PCR
Total RNA was extracted using the RNeasy Mini Kit (Qiagen
Australia, Doncaster, VIC, Australia) and reverse transcription
performed by using the RevertAid First strand cDNA. MKP-1, IL-
6 and IL-8 mRNA levels were measured using real-time RT-PCR
on an ABI Prism 7500 (Applied Biosystems, Foster City, CA) with
the MKP-1 (DUSP1: Hs00610256_g1), IL-6 (Hs00174131_m1) or
IL-8 (Hs00174103_m1) TaqManH Gene Expression Assays and
the eukaryotic 18S rRNA endogenous control probe (Applied
Biosystems) subjected to the following cycle parameters: 50uC for
2 min, 1 cycle; 95uC for 10 min, 1 cycle; 95uC for 15 s, 60uC for
1 min, 40 cycles and mRNA expression (fold increase) quantified
by delta delta Ct calculations.
ELISAs
Cell supernatants were collected and stored at 220uC for later
analysis by ELISA. IL-6 and IL-8 ELISAs were performed
according to the manufacturer’s instructions (BD Biosciences
Pharmingen, San Diego, CA).
Figure 2. Formoterol increases fluticasone-induced MKP-1 protein upregulation. (A) Growth-arrested ASM cells were treated with vehicle,
formoterol (10 nM), fluticasone (1 nM), formoterol (10 nM)+fluticasone (1 nM), for 0, 0.5, 1, 2, 4, 8, and 24 h. MKP-1 protein (molecular
weight:,39 kDa) was quantified by Western blotting, using a-tubulin as the loading control (molecular weight:,55 kDa), where (A) illustrates
representative Western blots and (B) demonstrates densitometric analysis where results are expressed as fold increase over 0 h and results for
fluticasone (from Figure 1B) shown graphically for comparative purposes (mean+SEM values from n= 3–8 primary ASM cell cultures). Statistical
analysis was performed using two-way ANOVA then Bonferroni’s post-test (where * indicates a significant effect of formoterol or fluticasone on MKP-
1 protein upregulation, compared to vehicle-treated cells, and 1 indicates a significant effect of formoterol on fluticasone-induced MKP-1 (P,0.05)).
doi:10.1371/journal.pone.0059635.g002
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MKP-1 siRNA Knock-down
Protein levels of MKP-1 were reduced by RNA interference and
the effect on cytokine secretion examined. ASM cells were
transiently transfected using nucleofection with 1 mg MKP-1-
specific SMART pool siRNA, consisting of a pool of four
individual siRNA from Dharmacon (Dharmacon, Lafayette, CO)
or a scrambled siRNA control, using methods established in our
previous publication [10]. Briefly, ASM cells were transfected with
the Nucleofector (Amaxa, Koln, Germany), using the basic kit for
primary smooth muscle cells with the manufacturer’s optimized
protocol of P-024. ASM cells were plated for 16 h after
transfection, before being growth-arrested for a further 24 h.
Cells were pretreated for 1 h with formoterol+fluticasone (along
with relevant controls) before stimulation for 24 h with TNFa
(10 ng/ml). Supernatants were then removed for IL-6 and IL-8
protein secretion by ELISA and lysates utilized for MKP-1
Western blotting (compared to a-tubulin as a loading control).
Statistical Analysis
Statistical analysis was performed using either Student’s
unpaired t tests, repeated measured ANOVA or two-way ANOVA
followed by Bonferroni’s multiple comparison tests. P values
,0.05 were sufficient to reject the null hypothesis for all analyses.
Results
Long-acting b2-agonists Increase Fluticasone-induced
MKP-1 Protein Upregulation.
Although MKP-1 is known to be corticosteroid-responsive
[10,20] and increased by cAMP-mediated signalling [20] in ASM
cells, the upregulation of this critical anti-inflammatory protein by
long-acting b2-agonists and clinically-used corticosteroids has been
incompletely examined to date. To address this, we examine here
for the first time, the effect of treating ASM cells with fluticasone,
alone or in combination with the long-acting b2-agonists -
salmeterol (100 nM: Figure 1) or formoterol (10 nM: Figure 2).
These concentrations of b2-agonists were chosen for the current
study as they had been used previously in in vitro investigations of
MKP-1 gene expression by Kaur et al. [12].
We first examined the temporal kinetics of MKP-1 protein
upregulation in ASM cells treated for up to 24 h with salmeterol or
fluticasone, alone or in combination (compared to vehicle-treated
controls). As shown in Figure 1A, salmeterol alone induced rapid,
but transient upregulation of MKP-1 with a peak at 1 h. In
contrast, fluticasone alone induced a sustained increase in MKP-1
protein upregulation; in accordance with our earlier report [10].
This was confirmed by densitometry (as shown in Figure 1B)
where salmeterol induced significantly greater levels of MKP-1
protein (4.861.0-fold) than cells treated with vehicle alone
(1.760.2-fold) at 1 h (P,0.05). While MKP-1 upregulation
induced by salmeterol was transient (returning back to basal levels
at 4 h), fluticasone significantly increased MKP-1 protein levels by
4.460.9-fold at 1 h and this increase was sustained for up to 24 h
(3.960.8-fold)((P,0.05). When we then treat cells with salmeterol
in combination with fluticasone (Figure 1A), the temporal pattern
of MKP-1 protein upregulation reflects the combined contribution
of the b2-agonist and corticosteroid. This is best demonstrated by
densitometric analysis (Figure 1B), where both drugs in combina-
tion are shown to act in an additive manner and salmeterol added
in combination with fluticasone induces significantly greater levels
of MKP-1 protein (8.261.4-fold), than fluticasone alone at 1 h
(4.460.9-fold) (P,0.05).
We then compared the effect of formoterol on fluticasone-
induced MKP-1 (Figure 2). In corroboration of our earlier report
[20], formoterol alone induces a transient increase in MKP-1
upregulation with a peak at 1–2 h (Figure 2A). Importantly,
Western blotting (Figure 2A) revealed that when formoterol and
fluticasone are added in combination, the peak of MKP-1
upregulation that appears at 1–2 h after the long-acting b2-agonist
and enhances the sustained pattern of MKP-1 upregulation
observed with fluticasone treatment alone. This is supported by
densitometric analysis where formoterol significantly increased
fluticasone-induced MKP-1 at 1 h (11.362.1-fold) and 2 h
(10.161.4-fold), compared to fluticasone alone at the same time
points (4.460.9- and 3.960.7-fold, respectively) (P,0.05).
Figure 3. Long-acting b2-agonists increase fluticasone-induced MKP-1 mRNA expression. Growth-arrested ASM cells were treated for 1 h
with vehicle, fluticasone (1 nM), salmeterol (100 nM), formoterol (10 nM), salmeterol (100 nM)+fluticasone (1 nM), formoterol (10 nM)+fluticasone
(1 nM). MKP-1 mRNA expression was quantified by real-time RT-PCR and results expressed as fold increase compared to vehicle-treated cells
(mean+SEM values from n= 9 primary ASM cell cultures). Statistical analysis was performed using repeated measures ANOVA with Bonferroni’s
multiple comparison test (where * denotes a significant increase in MKP-1 mRNA expression and 1 denotes a significant effect of the b2-agonists on
fluticasone-induced MKP-1 mRNA expression (P,0.05)).
doi:10.1371/journal.pone.0059635.g003
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Long-acting b2-agonists Increase Fluticasone-induced
MKP-1 mRNA Expression
MKP-1 is an immediate-early gene and we previously reported
that the corticosteroid dexamethasone and the long-acting b2-
agonist formoterol rapidly increased MKP-1 gene expression by
1 h [20]. In the current study we extend these observations and
perform a side-by-side comparison of MKP-1 mRNA upregula-
tion in response to the long-acting b2-agonists salmeterol and
formoterol, and the corticosteroid fluticasone, alone and in
combination. While MKP-1 gene expression induced by flutica-
sone (5.761.2-fold, compared to vehicle-treated cells) trended
towards significance, salmeterol and formoterol added alone
significantly increased MKP-1 gene expression by 10.262.8-fold
and 16.463.2-fold, respectively (P,0.05). Importantly, when long-
acting b2-agonists were added in combination with fluticasone
they significantly augmented steroid-induced MKP-1 mRNA
expression (P,0.05). As shown in Figure 3, salmeterol increased
MKP-1 expression to 16.463.2-fold and formoterol to 21.363.5-
fold, compared to fluticasone alone (5.761.2-fold, respectively)
(P,0.05).
Figure 4. Effect of long-acting b2-agonists on IL-6 and IL-8 mRNA expression and secretion. (A, B, C, D) Growth-arrested ASM cells were
treated with vehicle, salmeterol (100 nM) or formoterol (10 nM). (A) IL-6 and (B) IL-8 mRNA expression was quantified by real-time RT-PCR at 1 h and
results expressed as fold increase compared to vehicle-treated cells (mean+SEM values from n=9 primary ASM cell cultures). (C) IL-6 and (D) IL-8
secretion was measured by ELISA at 24 h and results are expressed as fold increase compared to vehicle-treated cells (where IL-6 and IL-8 protein
levels in cells treated with vehicle were 295.0634.8 and 26.364.6 pg/ml, respectively (mean+SEM values from n= 6 primary ASM cell cultures)).
Statistical analysis was performed using repeated measures ANOVA with Bonferroni’s multiple comparison test (where * denotes a significant
increase in mRNA expression or secretion (P,0.05)). (E, F) Growth-arrested ASM cells were treated with vehicle, dibutyryl cAMP (1 mM), forskolin
(10 mM) and (E) IL-6 and (F) IL-8 mRNA expression was quantified by real-time RT-PCR at 1 h. Results are expressed as fold increase compared to
vehicle-treated cells (mean+SEM values from n=3 primary ASM cell cultures). Statistical analysis was performed using the Student’s unpaired t test
where * denotes a significant increase in mRNA expression or secretion (P,0.05).
doi:10.1371/journal.pone.0059635.g004
LABA Increase Steroid-Induced MKP-1
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Effect of Long-acting b2-agonists on IL-6 and IL-8 mRNA
Expression and Secretion
As the final aim of the current study was to demonstrate the
anti-inflammatory function of MKP-1 on ASM synthetic function
by measuring repression of IL-6 and IL-8 secretion induced by
TNFa (see next section), it was first important to examine the
effects of b2-agonists alone on secretion of these cytokines by ASM
cells. Interestingly, IL-6 (like MKP-1) is cAMP-responsive. In this
way, we show that salmeterol and formoterol significantly enhance
IL-6 mRNA expression at 1 h (Figure 4A) and that formoterol
increases IL-6 secretion from ASM cells at 24 h (Figure 4C)
(P,0.05). These protein secretion results are in confirmation of
our earlier study [21] and in accord with the relative ability of
these b2-agonists to elevate cAMP in ASM cells [21]. The
involvement of cAMP/adenylate cyclase-mediated pathway in IL-
6 mRNA expression is further substantiated by treatment of ASM
cells with the cell-permeable cAMP analogue, dibutyryl cAMP,
and the adenylate cyclase activator, forskolin. As shown in
Figure 4E, dibutyryl cAMP and forskolin increased IL-6 mRNA
expression by 2.460.4-fold and 18.861.7-fold, respectively,
compared to vehicle control (P,0.05). IL-8, in contrast, is not
regulated by cAMP and thus long-acting b2-agonists do not
increase IL-8 mRNA expression (Figure 4B), nor protein secretion
(Figure 4D) in ASM cells. Moreover, dibutyryl cAMP and
forskolin are without effect on IL-8 mRNA expression (Figure 4F).
The Effect of Long-acting b2-agonists and Fluticasone,
Alone or in Combination, on Repression of TNFa-induced
IL-6 and IL-8 Secretion
Finally, the effect of MKP-1 upregulation induced by b2-
agonists, alone or in combination with the corticosteroid
fluticasone, was demonstrated by pretreating ASM cells for 1 h
before stimulation with TNFa. As shown in Figure 5A, and
explained by the cAMP-responsiveness of IL-6 (described earlier),
formoterol significantly enhanced TNFa-induced IL-6 secretion.
Despite this, when b2-agonists were added in combination with
fluticasone they still significantly repressed TNFa-induced IL-6
(P,0.05). IL-8, on the other hand, is not cAMP-responsive; thus,
b2-agonists did not significantly increase TNFa-induced IL-8
(Figure 5B). Interestingly, fluticasone alone did not repress TNFa-
induced IL-8, while salmeterol, or formoterol, in combination with
fluticasone significantly inhibited IL-6 secretion (Figure 5B). The
combination of the long-acting b2-agonists with fluticasone, has a
statistically greater effect than fluticasone alone on TNFa-induced
IL-8 secretion (P,0.05). Taken together, our results indicate that
long-acting b2-agonists increase fluticasone-induced MKP-1 in an
additive manner and in this way MKP-1 acts to repress cytokine
secretion from ASM cells.
In preliminary studies, we then knocked-down MKP-1 with
siRNA in an attempt to reverse the repression of cytokine secretion
by formoterol and fluticasone, in combination. Although MKP-1
siRNA successfully reduced protein levels of MKP-1 in ASM cells
(Figure 6A) we were unable to reverse the inhibition of TNFa-
induced IL-6 (Figure 6B) or IL-8 (Figure 6C) secretion by
formoterol and fluticasone. Investigations are now ongoing to
examine the hypothesis that in the absence of MKP-1, the p38
MAPK-dependent RNA destabilizing factor – tristetraprolin
(TTP) – may serve in a compensatory manner to repress
inflammation. However further studies will be required to fully
understand how these critical anti-inflammatory molecules are
intrinsically intertwined and act together as a fail-safe mechanism
to regulate inflammation in health and disease.
Discussion
This study demonstrates that long-acting b2-agonists increase
fluticasone-induced MKP-1 mRNA expression and protein upre-
gulation in ASM cells and together these asthma drugs have
significant effects on cytokine secretion from ASM, an important
immunomodulatory cell type in asthma.
Long-acting b2-agonists mediate their actions via interaction
with the b2-adrenergic receptor, activation of adenylate cyclase
and production of cAMP. Gene transcription is then induced in
genes that contain cAMP-responsive elements (CRE) in their 59-
promoter. MKP-1 has a CRE-containing promoter [7,8] and we
recently reported that the long-acting b2-agonist formoterol
induced MKP-1 mRNA and protein expression in a cAMP-
mediated manner via the b2-adrenergic receptor-protein kinase A
pathway [15]. MKP-1 gene expression and protein upregulation
was rapid and peaked by 1 h [15]. We confirm these studies here
and extend them to show that another commonly-used long-acting
b2-agonist, salmeterol, also rapidly upregulates MKP-1 in a
similar manner. Taken together with the demonstration that
MKP-1 can be upregulated by cAMP analogues [20] these results
present a unifying explanation that agonists that act to increase
cAMP will increase MKP-1. Indeed, this has proven to be the case
Figure 5. The effect of long-acting b2-agonists and fluticasone,
alone or in combination, on repression of TNFa-induced IL-6
and IL-8 secretion. Growth-arrested ASM cells were pretreated for 1 h
with vehicle, salmeterol (100 nM) or formoterol (10 nM), alone or in
combination with fluticasone (1 nM), before stimulation for 24 h with
TNFa (10 ng/ml). (A) IL-6 and (B) IL-8 secretion was measured by ELISA
and results expressed as (A) % TNFa-induced IL-6 secretion or (B) %
TNFa-induced IL-8 secretion (where TNFa-induced IL-6 and IL-8 protein
secretion was 5153.96618.9 and 5913.16480.0 pg/ml, respectively
(mean+SEM values from n=6 primary ASM cell cultures)). Statistical
analysis was performed using repeated measures ANOVA with
Bonferroni’s multiple comparison test where * denotes a significant
increase in IL-6 secretion and 1 denotes a significant repression of
TNFa-induced cytokine secretion (P,0.05).
doi:10.1371/journal.pone.0059635.g005
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for sphingosine 1-phosphate (S1P), a bioactive sphingolipid known
to be elevated in asthma [22]. S1P acts via Gs-coupled receptors to
increase cAMP [22] and we recently demonstrated that S1P
increased MKP-1 in a cAMP-dependent manner to serve an
important role a negative feedback controller and restrain the
extent and duration of pro-inflammatory cellular signalling [20].
Importantly, when long-acting b2-agonists are added in
combination with the corticosteroid fluticasone they significantly
and rapidly upregulated MKP-1 protein and mRNA expression.
The temporal pattern of MKP-1 protein upregulation reflects the
additive contribution of each asthma drug. That is, b2-agonists
rapidly, but transiently, upregulates MKP-1 at 1–2 h, while
corticosteroids induced a sustained increase in MKP-1 protein.
Thus, when added together they upregulate MKP-1 early (by 1 h)
but in a sustained manner. This additive upregulation was
supported by mRNA levels. These results suggest a molecular
basis for the added anti-inflammatory effects of both asthma drugs
in combination.
To support the above assertion that increased expression of
MKP-1 may explain the beneficial effects of b2-agonists/cortico-
steroid combination therapies in the repression of inflammatory
gene expression in asthma [16], we performed in vitro studies
measuring secretion of IL-6 and IL-8 from ASM cells after
stimulation with TNFa. It is important to note that IL-6 is a
cAMP-responsive gene. The 59-promoter for IL-6 contains a CRE
[21] and can be induced by cAMP analogues, as well as short-
acting and long-acting b2-agonists [21,23]. Herein we confirmed
the cAMP-responsiveness of IL-6 by demonstrating significant IL-
6 mRNA expression induced by the cell-permeable analogue,
dibutyryl cAMP, as well as the adenylate cyclase activator,
forskolin. In contrast, cAMP is only a weak activator of IL-8 in
ASM cells [24] and, as highlighted by Holden et al. in lung
epithelial cells [25], the promoter for IL-8 does not contain CRE
consensus sequences [26] and that transcriptional regulation may
involve cross-talk between transcription factors. Our current study
demonstrates the lack of effect of cAMP-elevating agents on IL-8
expression in ASM cells.
Thus, due to the cAMP-dependence of IL-6 expression, the
long-acting b2-agonist formoterol significantly enhanced TNFa-
induced IL-6 secretion. This corroborated our earlier report [21]
and underscored the importance of the study by Holden et al. [25]
where the authors stated that enhancement of IL-6 (and IL-8)
release by b2-agonists may contribute to the deleterious effects of
b2-agonist used monotherapy. Notably, when added in combina-
tion with fluticasone, b2-agonists significantly repressed IL-6
secretion, but not to a greater extent than fluticasone alone.
These results are in agreement with Holden et al. where increased
inflammatory cytokine released was reversed by corticosteroid
action [25].
The repressive effect on TNFa-induced IL-8 were more clear-
cut, as long-acting b2-agonists added on their own did not increase
IL-8 expression. Importantly, we observed that fluticasone alone
was without repressive effect on TNFa-induced IL-8 secretion, but
that b2-agonists added in combination significantly repressed
TNFa-induced IL-8. This enhanced repressive effect of b2-
agonists and corticosteroids correlates with the increased MKP-1
Figure 6. Effect of MKP-1 siRNA. ASM cells were transiently transfected using nucleofection with scrambled control or MKP-1 siRNA, growth-
arrested, then pretreated for 1 h with formoterol (10 nM)+fluticasone (1 nM) (along with relevant controls) before stimulation for 24 h with TNFa
(10 ng/ml). Supernatants were then removed for IL-6 and IL-8 protein secretion by ELISA and lysates utilized for MKP-1 Western blotting (compared
to a-tubulin as a loading control). (A) illustrates a representative Western blot, while (B, C) demonstrates results expressed as % TNFa-induced (B) IL-6
or (C) IL-8 secretion in cells transfected with scrambled control siRNA (mean+SEM values from n=6 primary ASM cell cultures).
doi:10.1371/journal.pone.0059635.g006
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expression by both asthma drugs in combination. Why the
combined effects of LABA/fluticasone on MKP-1 result in an
additive suppressive effect on IL-8, but not on IL-6, cannot be
completely delineated at this stage, but may reflect the relative
MAPK-dependent contribution to IL-6 and IL-8 secretion.
However, our in vitro results support those recently published
in vivo in mild asthmatics [27], where formoterol in combination
with corticosteroids improved clinical symptoms (FEV1) and
reduced IL-8 in a manner linked to MKP-1 upregulation.
Interestingly, it has been previously shown by Knobloch et al.
[28] that the corticosteroid dexamethasone suppresses IL-8 in
ASM cells of non-smokers and smokers, but not in those of
COPD; whether MKP-1 is involved warrants further investiga-
tion.
Our preliminary studies have raised the hypothesis that in the
absence of MKP-1 (knocked-down by siRNA), the p38 MAPK-
dependent TTP may be upregulated and serve as a compensatory
anti-inflammatory factor. TTP is an immediate-early gene [29]
that is rapidly and robustly expressed via p38 MAPK signalling
[30,31,32,33]. Moreover, TTP’s function as an mRNA destabilis-
ing factor is dictated by phosphorylation on two key serine residues
(S52 and S178). Further studies investigating the regulation of the
RNA destabilising factor TTP by MKP-1, and visa versa, in ASM
cells are warranted.
In summary, long-acting b2-agonists increase fluticasone-
induced MKP-1 in ASM cells and together these asthma drugs
have significant repressive effects on cytokine secretion from ASM
cells. This study further substantiates the anti-inflammatory role
played by MKP-1 as an important molecular mechanism
responsible for the improved anti-inflammatory action of cortico-
steroids and long-acting b2-agonists in combination in asthma.
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